If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Emgality Summary of Product Characteristics (SmPC)
Emgality®▼ (galcanezumab) Device: Information on Air Bubbles
It is normal to have air bubbles in the pen or syringe. The medicine is injected under the skin (subcutaneous injection).
Additional
Information
The
presence of the air bubble is due to the syringe manufacturing
process.It
will not cause harm or affect the accuracy of the dose.1
Patients
should not try to remove or expel the air bubble in the device.
Removal of the air bubble before injecting is not necessary and not
recommended.1
The
instructions for using the pen or syringe included with the Package
Leaflet, must be followed carefully. The pre-filled pen and
pre-filled syringe is for total use only.2
After
training, patients may self-inject galcanezumab if a healthcare
professional determines that it is appropriate.3
References
1.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2.
Emgality [instructions for use]. Eli Lilly Nederland B.V., The
Netherlands.
3.
Emgality [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
▼ This
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:February 13, 2019
Was this answer helpful to you?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com